AU2016282350A1 - Targeted enrichment of long nucleotide sequences using microfluidic partitioning - Google Patents
Targeted enrichment of long nucleotide sequences using microfluidic partitioning Download PDFInfo
- Publication number
- AU2016282350A1 AU2016282350A1 AU2016282350A AU2016282350A AU2016282350A1 AU 2016282350 A1 AU2016282350 A1 AU 2016282350A1 AU 2016282350 A AU2016282350 A AU 2016282350A AU 2016282350 A AU2016282350 A AU 2016282350A AU 2016282350 A1 AU2016282350 A1 AU 2016282350A1
- Authority
- AU
- Australia
- Prior art keywords
- dna
- droplets
- primer
- target
- target dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 13
- 238000000638 solvent extraction Methods 0.000 title claims description 4
- 238000000034 method Methods 0.000 claims abstract description 107
- 239000002773 nucleotide Substances 0.000 claims abstract description 28
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 28
- 108020004414 DNA Proteins 0.000 claims description 502
- 239000000523 sample Substances 0.000 claims description 196
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 148
- 230000003321 amplification Effects 0.000 claims description 145
- 102000053602 DNA Human genes 0.000 claims description 127
- 241000588724 Escherichia coli Species 0.000 claims description 45
- 239000003153 chemical reaction reagent Substances 0.000 claims description 44
- 241000282414 Homo sapiens Species 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 238000011895 specific detection Methods 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 239000011541 reaction mixture Substances 0.000 claims description 18
- 238000011529 RT qPCR Methods 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 238000009396 hybridization Methods 0.000 claims description 10
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 9
- 101100077755 Rattus norvegicus Mpp3 gene Proteins 0.000 claims description 7
- 239000012807 PCR reagent Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 101150072448 thrB gene Proteins 0.000 claims description 5
- 108091093088 Amplicon Proteins 0.000 claims description 4
- 101150063051 hom gene Proteins 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 101150014006 thrA gene Proteins 0.000 claims description 3
- 101000742087 Bacillus subtilis (strain 168) ATP-dependent threonine adenylase Proteins 0.000 claims description 2
- 101100278473 Drosophila melanogaster PolZ1 gene Proteins 0.000 claims description 2
- 101710113436 GTPase KRas Proteins 0.000 claims description 2
- 101000774739 Thermus thermophilus Aspartokinase Proteins 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 241000341657 Human papillomavirus type 18 Species 0.000 claims 5
- 241000701122 Human adenovirus 18 Species 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 58
- 238000002955 isolation Methods 0.000 abstract description 7
- 238000013537 high throughput screening Methods 0.000 abstract description 3
- 238000001514 detection method Methods 0.000 description 85
- 238000006243 chemical reaction Methods 0.000 description 75
- 239000003921 oil Substances 0.000 description 38
- 239000013615 primer Substances 0.000 description 30
- 239000002987 primer (paints) Substances 0.000 description 30
- 238000012163 sequencing technique Methods 0.000 description 29
- 239000000047 product Substances 0.000 description 28
- 239000012071 phase Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 21
- 239000000839 emulsion Substances 0.000 description 17
- 239000002480 mineral oil Substances 0.000 description 15
- 235000010446 mineral oil Nutrition 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 238000000137 annealing Methods 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000007481 next generation sequencing Methods 0.000 description 8
- 238000003260 vortexing Methods 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000013611 chromosomal DNA Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 6
- 238000013412 genome amplification Methods 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000001712 DNA sequencing Methods 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000001351 cycling effect Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000007480 sanger sequencing Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- -1 Mg++ ion Chemical class 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000239226 Scorpiones Species 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 241000701844 Bacillus virus phi29 Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 101150108175 Dusp3 gene Proteins 0.000 description 2
- 101100332370 Homo sapiens DUSP3 gene Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004720 dielectrophoresis Methods 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UQDUPHDELLQMOV-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctan-1-ol Chemical compound OC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F UQDUPHDELLQMOV-UHFFFAOYSA-N 0.000 description 1
- PJDOLCGOTSNFJM-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctan-1-ol Chemical compound OCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F PJDOLCGOTSNFJM-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101900350803 Escherichia coli Homoserine kinase Proteins 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 229910000514 dolomite Inorganic materials 0.000 description 1
- 239000010459 dolomite Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001036 exonucleolytic effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 239000011807 nanoball Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185111P | 2015-06-26 | 2015-06-26 | |
| US62/185,111 | 2015-06-26 | ||
| DKPA201570449 | 2015-07-07 | ||
| DKPA201570449 | 2015-07-07 | ||
| PCT/EP2016/064719 WO2016207379A1 (en) | 2015-06-26 | 2016-06-24 | Targeted enrichment of long nucleotide sequences using microfluidic partitioning |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016282350A1 true AU2016282350A1 (en) | 2018-01-18 |
Family
ID=57584736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016282350A Abandoned AU2016282350A1 (en) | 2015-06-26 | 2016-06-24 | Targeted enrichment of long nucleotide sequences using microfluidic partitioning |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10738354B2 (enExample) |
| EP (2) | EP3770271B1 (enExample) |
| JP (1) | JP6936155B2 (enExample) |
| AU (1) | AU2016282350A1 (enExample) |
| CA (1) | CA2990092A1 (enExample) |
| DK (1) | DK3770271T3 (enExample) |
| WO (1) | WO2016207379A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015189336A1 (en) * | 2014-06-11 | 2015-12-17 | Samplix S.A.R.L. | Nucleotide sequence exclusion enrichment by droplet sorting (needls) |
| JP2018203724A (ja) * | 2017-05-31 | 2018-12-27 | キヤノン株式会社 | 油性組成物、およびそれを用いた分析方法 |
| DK182109B1 (en) | 2019-08-02 | 2025-08-18 | Samplix Aps | System and method for amplifying nucleic acids from single cells |
| US20210214769A1 (en) * | 2020-01-13 | 2021-07-15 | Fluent Biosciences Inc. | Methods and systems for amplifying low concentrations of nucleic acids |
| DK181994B1 (en) * | 2021-09-28 | 2025-05-15 | Samplix Aps | Instrument for sorting of particles |
| EP4255632A1 (en) | 2020-12-01 | 2023-10-11 | Samplix ApS | System and method for sorting of particles |
| DK181862B1 (en) * | 2022-03-21 | 2025-02-24 | Samplix Aps | Method and kit for targeted enrichment of large dna molecules for long-read sequencing using facs or microfluidic partitioning |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107267596A (zh) | 2009-06-15 | 2017-10-20 | 考利达基因组股份有限公司 | 用于长片段阅读测序的方法和组合物 |
| US20120164633A1 (en) | 2010-12-27 | 2012-06-28 | Ibis Biosciences, Inc. | Digital droplet sequencing |
| JP6522511B2 (ja) | 2012-12-21 | 2019-05-29 | サンプリクス アンパーツゼルスカブ | ヌクレオチド配列の確率指向性単離（ｐｉｎｓ） |
| US20140303005A1 (en) | 2013-04-05 | 2014-10-09 | Raindance Technologies, Inc. | Rare cell analysis after negative selection |
| WO2014172373A2 (en) | 2013-04-19 | 2014-10-23 | Raindance Technologies, Inc | Digital analyte analysis |
| WO2015189336A1 (en) * | 2014-06-11 | 2015-12-17 | Samplix S.A.R.L. | Nucleotide sequence exclusion enrichment by droplet sorting (needls) |
| EP3160654A4 (en) * | 2014-06-27 | 2017-11-15 | The Regents of The University of California | Pcr-activated sorting (pas) |
-
2016
- 2016-06-24 EP EP20191574.1A patent/EP3770271B1/en active Active
- 2016-06-24 CA CA2990092A patent/CA2990092A1/en active Pending
- 2016-06-24 JP JP2017566728A patent/JP6936155B2/ja active Active
- 2016-06-24 WO PCT/EP2016/064719 patent/WO2016207379A1/en not_active Ceased
- 2016-06-24 EP EP16732595.0A patent/EP3314012B1/en active Active
- 2016-06-24 DK DK20191574.1T patent/DK3770271T3/da active
- 2016-06-24 AU AU2016282350A patent/AU2016282350A1/en not_active Abandoned
- 2016-06-24 US US15/739,541 patent/US10738354B2/en active Active
-
2020
- 2020-07-06 US US16/921,103 patent/US11572584B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3314012A1 (en) | 2018-05-02 |
| CA2990092A1 (en) | 2016-12-29 |
| US20200332353A1 (en) | 2020-10-22 |
| EP3770271B1 (en) | 2023-02-08 |
| EP3314012B1 (en) | 2020-09-09 |
| WO2016207379A1 (en) | 2016-12-29 |
| EP3770271A1 (en) | 2021-01-27 |
| US11572584B2 (en) | 2023-02-07 |
| JP6936155B2 (ja) | 2021-09-15 |
| JP2018518968A (ja) | 2018-07-19 |
| US20180179589A1 (en) | 2018-06-28 |
| DK3770271T3 (da) | 2023-05-08 |
| US10738354B2 (en) | 2020-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11390906B2 (en) | Nucleotide sequence exclusion enrichment by droplet sorting (NEEDLS) | |
| AU2016282350A1 (en) | Targeted enrichment of long nucleotide sequences using microfluidic partitioning | |
| AU2021290268A1 (en) | Immunorepertoire normality assessment method and its use | |
| EP3387148A1 (en) | Method for transcriptome analysis of single cells | |
| KR20170131516A (ko) | 혈액 샘플 내의 순환 종양 세포의 디지털 분석 | |
| IL280521B (en) | Suspended markers for colon and rectal cancer | |
| CN100429307C (zh) | 核酸检测方法及其系统 | |
| JP2022145606A (ja) | 核酸の正確な並行定量のための高感度な方法 | |
| AU2014279672A1 (en) | Improved NGS workflow | |
| EP4234712B1 (en) | Identification of cognate pairs of ligands and receptors | |
| CN119895048A (zh) | 用于单细胞核酸测序的组合索引 | |
| WO2015189685A2 (en) | Improved ngs workflow | |
| KR20150017525A (ko) | 차세대 염기서열 분석법을 이용한 체성돌연변이 검출방법 | |
| Freeman | Differential Display of Gene Expression | |
| EP3927841A1 (en) | Improved nucleic acid target enrichment and related methods | |
| HK1219117B (zh) | 使用拼装序列扩增片段化的目标核酸的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |